Employing a unique antibody generation platform based on Immune Tolerance Breaking Technology to generate therapeutic candidate leads with differentiated biological profile and enhanced druggability attributes.
Our translational research generates PK, PD, Tox and immunogenicity data through validated quantitative platforms, and enables us to model clinical responses to our investigational agents for better understanding of PK/PD/Safety profiles, which guides design and conduct of clinical studies.
We can leverage both classical fed-batch and perfusion-based continuous bioprocessing technologies to enable fast-to-IND and fast-to-market process development.
Based in Beijing, Shanghai, Guangzhou and Princeton, US, our teams at global clinical development centers and regulatory teams have extensive knowledge and experience in designing and executing clinical trials at all stages.
Equipped with a flexible modular manufacturing facility and advanced next-generation perfusion bioprocessing platform, we are able to significantly accelerate process development and reduce the cost of manufacturing.